The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients

Regional lymph nodes (RLNs) removed combined with surgery is a standard option for patients at stage I to IIIA NSCLC. The objective of the study is to clarify the effect of removing different number of RLNs on survival outcomes for patients at stage IIIA N0 NSCLC. Patients at stage IIIA N0 NSCLC fro...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Cancer 2023-01, Vol.14 (11), p.2093-2108
Main Authors: Wang, Yukun, Liu, Zixuan, Zhou, Zhonghua, Rao, Hanyu, Xiong, Jie, Xie, Shuanshuan
Format: Article
Language:English
Subjects:
Cancer therapies
Lung cancer
Lymphatic system
Medical prognosis
Mortality
Radiation
Research Paper
Surgery
Tumors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c404t-4ba8fff33d415180430eb1b9e242955d5f3d40d875cdde24546f787709a516f3
cites
container_end_page 2108
container_issue 11
container_start_page 2093
container_title Journal of Cancer
container_volume 14
creator Wang, Yukun
Liu, Zixuan
Zhou, Zhonghua
Rao, Hanyu
Xiong, Jie
Xie, Shuanshuan
description Regional lymph nodes (RLNs) removed combined with surgery is a standard option for patients at stage I to IIIA NSCLC. The objective of the study is to clarify the effect of removing different number of RLNs on survival outcomes for patients at stage IIIA N0 NSCLC. Patients at stage IIIA N0 NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Prior propensity score method (PSM), survival time was compared among different number (0, 1-3 and ≥4) of RLNs removed groups. After PSM, lung cancer-specific survival (LCSS) and overall survival (OS) were compared. Kaplan-Meier analysis and Cox regression analyses were used to clarify the impact of the factors on the prognosis with hazard ratio (HR) and 95% confidence interval (CI). A total of 11,583 patients at stage IIIA N0 NSCLC were included. Prior PSM, survival indicators including 1-year mortality rate, 5-year mortality rate, median survival time (MDST) and mean survival time (MST) from good to bad were all: ≥4, 1-3 and none RLNs removed group. After PSM, Kaplan-Meier survival analyses and univariate Cox regression analyses on OS and LCSS revealed a statistically significance on survival curve (
doi_str_mv 10.7150/jca.86495
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10367914</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2843036441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-4ba8fff33d415180430eb1b9e242955d5f3d40d875cdde24546f787709a516f3</originalsourceid><addsrcrecordid>eNpdkVtLxDAQhYMoKuqDf0ACvujDarKZNO2TyOKlsKyii68hzWW3S9usSSv4741X1HnJMPNx5pCD0CElZ4Jycr7S6izPoOAbaJfmTIyKLIPNX_0OOohxRVKxYiyAbaMdJqAQQOkuMvOlxU-qGVTVWHwf_KLzsa81Ltu10j32Dj_YRe071eDpa7te4pk3Ns1a_2IN9h2-G3rtWxux8wGXZXmJZwTPHifTCb5XfW27Pu6jLaeaaA--3j00v76aT25H07ubcnI5HWkg0I-gUrlzjjEDlNOcACO2olVhxzAuODfcpQ0xueDamDTkkDmRC0EKxWnm2B66-JRdD1VrjU6ng2rkOtStCq_Sq1r-3XT1Ui78i6SEZaKgkBROvhSCfx5s7GVbR22bRnXWD1GO8-SJZQA0ocf_0JUfQvqmD4pkDCiIRJ1-Ujr4GIN1P24oke_xyRSf_IgvsUe_7f-Q32GxN9Fek5U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2840634147</pqid></control><display><type>article</type><title>The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients</title><source>PubMed (Medline)</source><source>Publicly Available Content (ProQuest)</source><creator>Wang, Yukun ; Liu, Zixuan ; Zhou, Zhonghua ; Rao, Hanyu ; Xiong, Jie ; Xie, Shuanshuan</creator><creatorcontrib>Wang, Yukun ; Liu, Zixuan ; Zhou, Zhonghua ; Rao, Hanyu ; Xiong, Jie ; Xie, Shuanshuan</creatorcontrib><description>Regional lymph nodes (RLNs) removed combined with surgery is a standard option for patients at stage I to IIIA NSCLC. The objective of the study is to clarify the effect of removing different number of RLNs on survival outcomes for patients at stage IIIA N0 NSCLC. Patients at stage IIIA N0 NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Prior propensity score method (PSM), survival time was compared among different number (0, 1-3 and ≥4) of RLNs removed groups. After PSM, lung cancer-specific survival (LCSS) and overall survival (OS) were compared. Kaplan-Meier analysis and Cox regression analyses were used to clarify the impact of the factors on the prognosis with hazard ratio (HR) and 95% confidence interval (CI). A total of 11,583 patients at stage IIIA N0 NSCLC were included. Prior PSM, survival indicators including 1-year mortality rate, 5-year mortality rate, median survival time (MDST) and mean survival time (MST) from good to bad were all: ≥4, 1-3 and none RLNs removed group. After PSM, Kaplan-Meier survival analyses and univariate Cox regression analyses on OS and LCSS revealed a statistically significance on survival curve ( &lt;0.001) between each two of the three groups (none, 1-3 and ≥4 RLNs removed group). Multivariable Cox regression analyses on OS and LCSS showed an independent association of RLNs removed with higher OS (HR, 0.275; 95% CI, 0.259-0.291; &lt;0.001) and LCSS (HR, 0.239; 95% CI, 0.224-0.256; &lt;0.001) compared with none RLN removed and no statistical difference with OS (HR, 1.118; 95% CI, 0.983-1.271; =0.088) and LCSS (HR, 1.107; 95% CI, 0.954-1.284; =0.179) between 1-3 RLNs removed and ≥4 RLNs removed. Removing RLNs was beneficial to survival outcomes of patients at stage IIIA N0 NSCLC. Compared with 1-3 RLNs removed, ≥4 RLNs removed could bring a better survival time but not an independent prognostic factor ( &gt;0.05).</description><identifier>ISSN: 1837-9664</identifier><identifier>EISSN: 1837-9664</identifier><identifier>DOI: 10.7150/jca.86495</identifier><identifier>PMID: 37497411</identifier><language>eng</language><publisher>Australia: Ivyspring International Publisher Pty Ltd</publisher><subject>Cancer therapies ; Lung cancer ; Lymphatic system ; Medical prognosis ; Mortality ; Radiation ; Research Paper ; Surgery ; Tumors</subject><ispartof>Journal of Cancer, 2023-01, Vol.14 (11), p.2093-2108</ispartof><rights>The author(s).</rights><rights>2023. This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The author(s) 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-4ba8fff33d415180430eb1b9e242955d5f3d40d875cdde24546f787709a516f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2840634147/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2840634147?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768,74869</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37497411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Yukun</creatorcontrib><creatorcontrib>Liu, Zixuan</creatorcontrib><creatorcontrib>Zhou, Zhonghua</creatorcontrib><creatorcontrib>Rao, Hanyu</creatorcontrib><creatorcontrib>Xiong, Jie</creatorcontrib><creatorcontrib>Xie, Shuanshuan</creatorcontrib><title>The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients</title><title>Journal of Cancer</title><addtitle>J Cancer</addtitle><description>Regional lymph nodes (RLNs) removed combined with surgery is a standard option for patients at stage I to IIIA NSCLC. The objective of the study is to clarify the effect of removing different number of RLNs on survival outcomes for patients at stage IIIA N0 NSCLC. Patients at stage IIIA N0 NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Prior propensity score method (PSM), survival time was compared among different number (0, 1-3 and ≥4) of RLNs removed groups. After PSM, lung cancer-specific survival (LCSS) and overall survival (OS) were compared. Kaplan-Meier analysis and Cox regression analyses were used to clarify the impact of the factors on the prognosis with hazard ratio (HR) and 95% confidence interval (CI). A total of 11,583 patients at stage IIIA N0 NSCLC were included. Prior PSM, survival indicators including 1-year mortality rate, 5-year mortality rate, median survival time (MDST) and mean survival time (MST) from good to bad were all: ≥4, 1-3 and none RLNs removed group. After PSM, Kaplan-Meier survival analyses and univariate Cox regression analyses on OS and LCSS revealed a statistically significance on survival curve ( &lt;0.001) between each two of the three groups (none, 1-3 and ≥4 RLNs removed group). Multivariable Cox regression analyses on OS and LCSS showed an independent association of RLNs removed with higher OS (HR, 0.275; 95% CI, 0.259-0.291; &lt;0.001) and LCSS (HR, 0.239; 95% CI, 0.224-0.256; &lt;0.001) compared with none RLN removed and no statistical difference with OS (HR, 1.118; 95% CI, 0.983-1.271; =0.088) and LCSS (HR, 1.107; 95% CI, 0.954-1.284; =0.179) between 1-3 RLNs removed and ≥4 RLNs removed. Removing RLNs was beneficial to survival outcomes of patients at stage IIIA N0 NSCLC. Compared with 1-3 RLNs removed, ≥4 RLNs removed could bring a better survival time but not an independent prognostic factor ( &gt;0.05).</description><subject>Cancer therapies</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Mortality</subject><subject>Radiation</subject><subject>Research Paper</subject><subject>Surgery</subject><subject>Tumors</subject><issn>1837-9664</issn><issn>1837-9664</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkVtLxDAQhYMoKuqDf0ACvujDarKZNO2TyOKlsKyii68hzWW3S9usSSv4741X1HnJMPNx5pCD0CElZ4Jycr7S6izPoOAbaJfmTIyKLIPNX_0OOohxRVKxYiyAbaMdJqAQQOkuMvOlxU-qGVTVWHwf_KLzsa81Ltu10j32Dj_YRe071eDpa7te4pk3Ns1a_2IN9h2-G3rtWxux8wGXZXmJZwTPHifTCb5XfW27Pu6jLaeaaA--3j00v76aT25H07ubcnI5HWkg0I-gUrlzjjEDlNOcACO2olVhxzAuODfcpQ0xueDamDTkkDmRC0EKxWnm2B66-JRdD1VrjU6ng2rkOtStCq_Sq1r-3XT1Ui78i6SEZaKgkBROvhSCfx5s7GVbR22bRnXWD1GO8-SJZQA0ocf_0JUfQvqmD4pkDCiIRJ1-Ujr4GIN1P24oke_xyRSf_IgvsUe_7f-Q32GxN9Fek5U</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Wang, Yukun</creator><creator>Liu, Zixuan</creator><creator>Zhou, Zhonghua</creator><creator>Rao, Hanyu</creator><creator>Xiong, Jie</creator><creator>Xie, Shuanshuan</creator><general>Ivyspring International Publisher Pty Ltd</general><general>Ivyspring International Publisher</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230101</creationdate><title>The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients</title><author>Wang, Yukun ; Liu, Zixuan ; Zhou, Zhonghua ; Rao, Hanyu ; Xiong, Jie ; Xie, Shuanshuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-4ba8fff33d415180430eb1b9e242955d5f3d40d875cdde24546f787709a516f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cancer therapies</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Mortality</topic><topic>Radiation</topic><topic>Research Paper</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Yukun</creatorcontrib><creatorcontrib>Liu, Zixuan</creatorcontrib><creatorcontrib>Zhou, Zhonghua</creatorcontrib><creatorcontrib>Rao, Hanyu</creatorcontrib><creatorcontrib>Xiong, Jie</creatorcontrib><creatorcontrib>Xie, Shuanshuan</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Yukun</au><au>Liu, Zixuan</au><au>Zhou, Zhonghua</au><au>Rao, Hanyu</au><au>Xiong, Jie</au><au>Xie, Shuanshuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients</atitle><jtitle>Journal of Cancer</jtitle><addtitle>J Cancer</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>14</volume><issue>11</issue><spage>2093</spage><epage>2108</epage><pages>2093-2108</pages><issn>1837-9664</issn><eissn>1837-9664</eissn><abstract>Regional lymph nodes (RLNs) removed combined with surgery is a standard option for patients at stage I to IIIA NSCLC. The objective of the study is to clarify the effect of removing different number of RLNs on survival outcomes for patients at stage IIIA N0 NSCLC. Patients at stage IIIA N0 NSCLC from 2004 to 2015 were identified from Surveillance, Epidemiology, and End Results (SEER) database. Prior propensity score method (PSM), survival time was compared among different number (0, 1-3 and ≥4) of RLNs removed groups. After PSM, lung cancer-specific survival (LCSS) and overall survival (OS) were compared. Kaplan-Meier analysis and Cox regression analyses were used to clarify the impact of the factors on the prognosis with hazard ratio (HR) and 95% confidence interval (CI). A total of 11,583 patients at stage IIIA N0 NSCLC were included. Prior PSM, survival indicators including 1-year mortality rate, 5-year mortality rate, median survival time (MDST) and mean survival time (MST) from good to bad were all: ≥4, 1-3 and none RLNs removed group. After PSM, Kaplan-Meier survival analyses and univariate Cox regression analyses on OS and LCSS revealed a statistically significance on survival curve ( &lt;0.001) between each two of the three groups (none, 1-3 and ≥4 RLNs removed group). Multivariable Cox regression analyses on OS and LCSS showed an independent association of RLNs removed with higher OS (HR, 0.275; 95% CI, 0.259-0.291; &lt;0.001) and LCSS (HR, 0.239; 95% CI, 0.224-0.256; &lt;0.001) compared with none RLN removed and no statistical difference with OS (HR, 1.118; 95% CI, 0.983-1.271; =0.088) and LCSS (HR, 1.107; 95% CI, 0.954-1.284; =0.179) between 1-3 RLNs removed and ≥4 RLNs removed. Removing RLNs was beneficial to survival outcomes of patients at stage IIIA N0 NSCLC. Compared with 1-3 RLNs removed, ≥4 RLNs removed could bring a better survival time but not an independent prognostic factor ( &gt;0.05).</abstract><cop>Australia</cop><pub>Ivyspring International Publisher Pty Ltd</pub><pmid>37497411</pmid><doi>10.7150/jca.86495</doi><tpages>16</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1837-9664
ispartof Journal of Cancer, 2023-01, Vol.14 (11), p.2093-2108
issn 1837-9664
1837-9664
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10367914
source PubMed (Medline); Publicly Available Content (ProQuest)
subjects Cancer therapies
Lung cancer
Lymphatic system
Medical prognosis
Mortality
Radiation
Research Paper
Surgery
Tumors
title The Valuable Prognostic Impact of Regional Lymph Node Removed on Outcomes for IIIA N0 NSCLC Patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T20%3A45%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Valuable%20Prognostic%20Impact%20of%20Regional%20Lymph%20Node%20Removed%20on%20Outcomes%20for%20IIIA%20N0%20NSCLC%20Patients&rft.jtitle=Journal%20of%20Cancer&rft.au=Wang,%20Yukun&rft.date=2023-01-01&rft.volume=14&rft.issue=11&rft.spage=2093&rft.epage=2108&rft.pages=2093-2108&rft.issn=1837-9664&rft.eissn=1837-9664&rft_id=info:doi/10.7150/jca.86495&rft_dat=%3Cproquest_pubme%3E2843036441%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c404t-4ba8fff33d415180430eb1b9e242955d5f3d40d875cdde24546f787709a516f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2840634147&rft_id=info:pmid/37497411&rfr_iscdi=true